@rokkzillaa's peptide stack claims need a reality check

What did @rokkzillaa actually say?

The creator pitched a five-compound stack for people who are "skinny fat": carrying stubborn midsection fat without being significantly overweight. The lineup was matzi (a GLP-1 receptor agonist), tesamorelin, 5-amino-1MQ, SLU-PP-332 ("sloop 3-2"), and GHK-copper. The core argument was that belly fat in this population exists because the body "isn't processing energy correctly," and each compound addresses a separate piece of that problem. He also explicitly told viewers not to use semaglutide for this use case, arguing it causes muscle loss in people without much fat to lose.

That framing is actually more thoughtful than most peptide content on this platform. Separating GLP-1 use cases by body composition context is a real clinical consideration. Whether the stack he recommends actually holds up is a different question entirely.

Does the science back this up?

Tesamorelin has the strongest evidence here, and the rest of the stack ranges from early animal data to outright research chemicals with zero human trials. That gap matters enormously.

Tesamorelin is FDA-approved, but specifically for HIV-associated lipodystrophy. The creator says there are "clinical trials showing it works against stubborn belly fat," which is accurate in a narrow sense. Falutz et al. (2010, New England Journal of Medicine) showed significant visceral fat reduction in a specific patient population. Applying that finding to otherwise healthy people chasing a flatter stomach is a stretch the data does not support.

5-amino-1MQ is an NNMT inhibitor. The enzyme-blocking mechanism the creator describes is roughly consistent with Neelakantan et al. (2019, Nature Communications), but that research was conducted in mice. No published human clinical trials exist for this compound as of 2024. SLU-PP-332 is an ERR agonist with rodent metabolic data (Dufour et al., 2021, Journal of Medicinal Chemistry). It has not been tested in humans for safety or efficacy. Calling it a practical training substitute is not supported by evidence.

What did they get wrong (or right)?

The GLP-1 warning deserves credit. The concern about muscle loss with semaglutide in leaner individuals is real. A 2023 analysis in Obesity noted that lean mass loss accounts for a disproportionately large share of weight lost in people with lower baseline BMI. Steering this population away from semaglutide is defensible advice.

The tesamorelin framing is where things get slippery. Saying it's "FDA approved" without noting that approval is disease-specific creates a false impression of regulatory validation for off-label cosmetic use. That is misleading by omission.

The largest problem is SLU-PP-332. Describing a compound with no human safety data as something that "mimics what exercise does to your metabolism" and positioning it as a practical gap-filler for people whose "training isn't where it needs to be yet" is genuinely irresponsible. Recommending it to 85,000 viewers without a single human trial on record is the kind of content that causes harm. The matzi framing about insulin sensitivity and belly fat is simplified but not fabricated. It reflects real metabolic biology, just stripped of nuance.

What should you actually know?

If you are dealing with stubborn visceral fat despite reasonable diet and training, insulin sensitivity is a legitimate area to explore with a physician. The creator's underlying framing there is not baseless. The problem is that the stack he recommends escalates quickly from a real clinical concern to compounds that have never been tested in humans.

Tesamorelin used off-label carries real considerations: it can raise blood glucose, requires injection, and its long-term safety profile outside of HIV-lipodystrophy patients is not well-characterized. Anyone evaluating it should do so with a physician, baseline metabolic labs, and a clear understanding that this is off-label use. 5-amino-1MQ and SLU-PP-332 sourced from gray-market peptide vendors carry unknown purity, unreliable dosing, and no regulatory oversight. The history of "works in mice" compounds failing or causing harm in humans is long and not reassuring. GHK-copper for cosmetic skin quality is the least objectionable item here. The evidence base is modest but real enough that it does not warrant the same level of concern as the research chemicals in this stack.